Drug Trial Radar · NCT03241342
Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence
Last checked: Nov 19, 2026Latest source record: Mar 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
491
Actual
Start
Aug 21, 2017
Primary completion
Sep 21, 2018
Study completion Sep 21, 2018
Sponsor
- Lead sponsor
- GTxIndustry
- Sponsor type
- Industry
- First posted
- Aug 7, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
GTx-024 is an orally bioavailable and tissue-selective nonsteroidal selective androgen receptor modulator (SARM) that has demonstrated androgenic and anabolic activity and is currently being evaluated as a potential treatment for stress urinary incontinence (SUI) in postmenopausal women. Urinary incontinence and pelvic floor disorders are major health problems for women, especially as they age. Pelvic floor muscle relaxation has been found to correlate with lower urinary tract symptoms including SUI. Muscles of the pelvic floor and lower urinary tract are crucial for supporting the pelvic organs and micturition; however, damage to the muscles or lack of hormonal stimulation are thought to contribute to pelvic organ prolapse and urinary incontinence. Although anabolic steroids may increase muscle mass and strength, lack of oral bioavailability and known potential risks have limited their use. Nonsteroidal SARMs have potential to achieve benefits of anabolic steroid therapy (improved muscle mass, cholesterol/triglyceride levels, glucose metabolism, and bone density) with fewer adverse effects, such as hirsutism and acne, in women. Both nonclinical and clinical data suggest that SARMs may provide a new therapeutic option for pelvic floor and lower urinary tract disorders, as both testosterone and its more potent metabolite, dihydrotestosterone, have anabolic effects on muscle.
Conditions
- Stress Urinary Incontinence
Interventions
GTx 024Drug
Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024.
PlaceboDrug
Placebo study drug is identical in appearance to the GTx-024 study drug and contains polyethylene glycol 400 but not GTx-024.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With a ≥ 50% Reduction From Baseline in the Mean Number of Stress Incontinence Episodes Per Day at Week 12Time frame: 12 Weeks
Locations
62 sites in 1 country. Site status is shown where the registry gives one.
Urology Center of Alabama
Homewood, Alabama
Coastal Clinical Research Inc
Mobile, Alabama
Alaska Clinical Research Center
Anchorage, Alaska
Mayo Clinic Arizona
Phoenix, Arizona
Urological Associates of Southern Arizona
Tucson, Arizona
Women's Healthcare Research Corporation
San Diego, California
American Institute of Research
Whittier, California
Genitourinary Surgical Consultants
Denver, Colorado
Urology Associates Research
Englewood, Colorado
Women's Health Specialty Care
Farmington, Connecticut
Coastal Connecticut Research, LLC
New London, Connecticut
Bladder Control Center of Connecticut
Norwalk, Connecticut
James A Simon MD PC
Washington D.C., District of Columbia
South Florida Medical Research
Aventura, Florida
Tampa Bay Medical Research Inc
Clearwater, Florida
Midland Florida Clinical Research Center LLC
DeLand, Florida
Precision Clinical Research
Lauderdale Lakes, Florida
Lone Star Research Center
Miami, Florida
Medical Research of Florida
Miami, Florida
Clinical Research Center of Florida
Pompano Beach, Florida
Mount Vernon Clinical Research LLC
Sandy Springs, Georgia
Clinical Research Prime
Idaho Falls, Idaho
Idaho Urologic Institue
Meridian, Idaho
Women's Health Institution of Illinois
Oak Lawn, Illinois
First Urology PSC
Jeffersonville, Indiana
Iowa Clinic
West Des Moines, Iowa
DelRicht Clinical Research, LLC
New Orleans, Louisiana
Regional Urology
Shreveport, Louisiana
Chesapeake Urology Associates PA
Hanover, Maryland
Boston Clinical Trials
Boston, Massachusetts
Bay State clinical Trials
Watertown, Massachusetts
Beyer Research
Kalamazoo, Michigan
William Beaumont Hospital Urology Research
Royal Oak, Michigan
Women's Clinic of Lincoln
Lincoln, Nebraska
Sheldon J Freedman MD Ltd
Las Vegas, Nevada
Premier Urology Group, LL
Edison, New Jersey
Lawrence Obs Gyn clinical Research
Lawrenceville, New Jersey
Delaware Valley Urology
Mount Laurel, New Jersey
Accumed Research Associates
Garden City, New York
Manhattan Medical Research Practice PLLC
New York, New York
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.